On October 16, 2019 ArQule, Inc. (Nasdaq: ARQL) reported that it will be presenting data on the company’s AKT inhibitor, ARQ 751, in two poster presentations at the 2019 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held from October 26th to October 30th, 2019 in Boston, Massachusetts (Press release, ArQule, OCT 16, 2019, View Source [SID1234542296]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations will detail clinical data demonstrating the correlation between biomarkers and patient response to treatment with ARQ 751 as well as preclinical in vivo and in vitro findings supporting the potential of ARQ 751 in combination with a variety of therapeutic agents.
Details on the presentations are as follows:
Presentation Title: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751
Abstract Number: A034
Presenter: Shubham Pant, M.D., MD Anderson Cancer Center
Date: October 27, 2019
Poster Viewing Time: 12:30 p.m.- 4:00 p.m. EDT
Location: Hall D, Hynes Convention Center
Presentation Title: In vitro and in vivo combination of ARQ 751 with PARP inhibitors, CDK4/6 inhibitors, Fulvestrant and Paclitaxel
Abstract Number: C076
Presenter: Yi Yu, Ph.D., ArQule
Date: October 29, 2019
Poster Viewing Time: 12:30 p.m.- 4:00 p.m. EDT
Location: Hall D, Hynes Convention Center
Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Publications & Presentations section of the ArQule website after the presentations conclude.
About ARQ 751
ARQ 751 is orally bioavailable, selective small molecule inhibitor of the AKT serine/threonine kinase. The AKT pathway when abnormally activated is implicated in multiple oncogenic processes such as cell proliferation and apoptosis. This pathway has emerged as a target of potential therapeutic relevance for compounds that inhibit its activity, which has been linked to a variety of cancers as well as to select non-oncology indications.